Determination of Potential Lead Compound from Magnolia officinalis for Alzheimer’s Disease through Pharmacokinetic Prediction, Molecular Docking, Dynamic Simulation, and Experimental Validation
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910507 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kumju Youn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Nutrition, Dong-A University, Busan 49315, Republic of Korea. Hauptthemen laut MEDLINE: Magnolia, Alzheimer Disease, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Foundation of Korea (NRF), Ministry of Education, Science, and Technology.
Themen: Simulation in der Pflegeausbildung, Demenz
Abstract (Originalsprache)
Amyloid β protein (Aβ) deposition has been implicated as the molecular driver of Alzheimer’s disease (AD) progression. The modulation of the formation of abnormal aggregates and their post-translational modification is strongly suggested as the most effective approach to anti-AD. Beta-site APP-cleaving enzyme 1 (BACE1) acts upstream in amyloidogenic processing to generate Aβ, which rapidly aggregates alone or in combination with acetylcholinesterase (AChE) to form fibrils. Accumulated Aβ promotes BACE1 activation via glycogen synthase kinase-3β (GSK-3β) and is post-translationally modified by glutaminyl cyclase (QC), resulting in increased neurotoxicity. A novel multi-target inhibitor as a potential AD agent was identified using an in silico approach and experimental validation. Magnolia officinalis, which showed the best anti-AD activity in our preliminary study, was subjected to analysis, and 82 compounds were studied. Among 23 compounds with drug-likeness, blood–brain barrier penetration, and safety, honokiol emerged as a lead structure for the inhibition of BACE1, AChE, QC, and GSK-3β in docking and molecular dynamics (MD) simulations. Furthermore, honokiol was found to be an excellent multi-target inhibitor of these enzymes with an IC50 of 6–90 μM, even when compared to other natural single-target inhibitors. Taken together, the present study is the first to demonstrate that honokiol acts as a multiple enzyme inhibitor with an excellent pharmacokinetic and safety profile which may provide inhibitory effects in broad-range areas including the overproduction, aggregation, and post-translational modification of Aβ. It also provides insight into novel structural features for the design and discovery of multi-target inhibitors for anti-AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food Science and Nutrition, Dong-A University, Busan 49315, Republic of Korea.
- Center for Food & Bio Innovation, Dong-A University, Busan 49315, Republic of Korea.
- Department of Health Sciences, The Graduate School of Dong-A University, Busan 49315, Republic of Korea.
ORCID-Profile: Kumju Youn
Förderung
- The National Research Foundation of Korea (NRF)
- Ministry of Education, Science, and Technology
Zitieren
APA
Youn, K., & Jun, M. (2024). Determination of Potential Lead Compound from Magnolia officinalis for Alzheimer’s Disease through Pharmacokinetic Prediction, Molecular Docking, Dynamic Simulation, and Experimental Validation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910507
Vancouver
Youn K, Jun M. Determination of Potential Lead Compound from Magnolia officinalis for Alzheimer’s Disease through Pharmacokinetic Prediction, Molecular Docking, Dynamic Simulation, and Experimental Validation. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910507
BibTeX
@article{Youn2024,
author = {Youn, Kumju and Jun, Mira},
title = {Determination of Potential Lead Compound from Magnolia officinalis for Alzheimer’s Disease through Pharmacokinetic Prediction, Molecular Docking, Dynamic Simulation, and Experimental Validation},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910507}
}
EUVIMED